Sichuan Kelun Pharmaceutical Co., Ltd. Class A Sichuan Kelun Pharmaceutical Co., Ltd. Class A

Sichuan Kelun Pharmaceutical Co., Ltd. Class A

002422

Rangering i aksjer #2010
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Aksjekurs
$6.40
Markedsverdi
$10.19B
Endring (1 dag)
-0.77%
Endring (1 år)
27.14%
Land
CN
Handel Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)

Kategori

Healthcare
Inntekter for Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Inntekter i Jun 2026 TTM: $2.74B
Ifølge de nyeste økonomiske rapportene til Sichuan Kelun Pharmaceutical Co., Ltd. Class A er selskapets nåværende inntekter (TTM) $2.74B. I 2024 hadde selskapet inntekter på $2.99B en nedgang sammenlignet med inntektene i 2023, som var $3.03B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Sichuan Kelun Pharmaceutical Co., Ltd. Class A fra 2007 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $2.74B 4.30%
2025 $2.62B -12.23%
2024 $2.99B -1.40%
2023 $3.03B 9.81%
2022 $2.76B 1.53%
2021 $2.72B 7.86%
2020 $2.52B -0.49%
2019 $2.53B 6.54%
2018 $2.38B 35.26%
2017 $1.76B 42.45%
2016 $1.23B 3.20%
2015 $1.20B -7.71%
2014 $1.30B 15.02%
2013 $1.13B 19.33%
2012 $943.78M 16.57%
2011 $809.60M 32.72%
2010 $610.02M 29.33%
2009 $471.69M 23.71%
2008 $381.28M 38.09%
2007 $276.12M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B 361.49%
US
$2.23B -18.55%
US
$15.74B 475.55%
AU
$10.11B 269.61%
BE
$6.02B 120.11%
NL